355 related articles for article (PubMed ID: 19253307)
1. Interleukin-23/Th17 pathways and inflammatory bowel disease.
Abraham C; Cho J
Inflamm Bowel Dis; 2009 Jul; 15(7):1090-100. PubMed ID: 19253307
[TBL] [Abstract][Full Text] [Related]
2. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease.
Abraham C; Cho JH
Annu Rev Med; 2009; 60():97-110. PubMed ID: 18976050
[TBL] [Abstract][Full Text] [Related]
3. The interleukin-23 axis in intestinal inflammation.
Ahern PP; Izcue A; Maloy KJ; Powrie F
Immunol Rev; 2008 Dec; 226():147-59. PubMed ID: 19161422
[TBL] [Abstract][Full Text] [Related]
4. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
Cătană CS; Berindan Neagoe I; Cozma V; Magdaş C; Tăbăran F; Dumitraşcu DL
World J Gastroenterol; 2015 May; 21(19):5823-30. PubMed ID: 26019446
[TBL] [Abstract][Full Text] [Related]
5. IL-23/IL-17 axis in IBD.
Sarra M; Pallone F; Macdonald TT; Monteleone G
Inflamm Bowel Dis; 2010 Oct; 16(10):1808-13. PubMed ID: 20222127
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease.
Globig AM; Hennecke N; Martin B; Seidl M; Ruf G; Hasselblatt P; Thimme R; Bengsch B
Inflamm Bowel Dis; 2014 Dec; 20(12):2321-9. PubMed ID: 25248005
[TBL] [Abstract][Full Text] [Related]
7. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid.
Rafa H; Saoula H; Belkhelfa M; Medjeber O; Soufli I; Toumi R; de Launoit Y; Moralès O; Nakmouche M; Delhem N; Touil-Boukoffa C
J Interferon Cytokine Res; 2013 Jul; 33(7):355-68. PubMed ID: 23472658
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice.
Elson CO; Cong Y; Weaver CT; Schoeb TR; McClanahan TK; Fick RB; Kastelein RA
Gastroenterology; 2007 Jun; 132(7):2359-70. PubMed ID: 17570211
[TBL] [Abstract][Full Text] [Related]
9. Total Glycosides of Peony Protects Against Inflammatory Bowel Disease by Regulating IL-23/IL-17 Axis and Th17/Treg Balance.
Li Q; Shan Q; Sang X; Zhu R; Chen X; Cao G
Am J Chin Med; 2019; 47(1):177-201. PubMed ID: 30612460
[TBL] [Abstract][Full Text] [Related]
10. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease.
Su J; Chen T; Ji XY; Liu C; Yadav PK; Wu R; Yang P; Liu Z
Inflamm Bowel Dis; 2013; 19(4):720-8. PubMed ID: 23429464
[TBL] [Abstract][Full Text] [Related]
11. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease.
Liu Z; Yang L; Cui Y; Wang X; Guo C; Huang Z; Kan Q; Liu Z; Liu Y
Inflamm Bowel Dis; 2009 Aug; 15(8):1133-44. PubMed ID: 19322899
[TBL] [Abstract][Full Text] [Related]
12. Immunopathogenesis of IBD: Batf as a Key Driver of Disease Activity.
Hildner K; Punkenburg E; Abendroth B; Neurath MF
Dig Dis; 2016; 34 Suppl 1():40-7. PubMed ID: 27548324
[TBL] [Abstract][Full Text] [Related]
13. Docosahexaenoyl serotonin, an endogenously formed n-3 fatty acid-serotonin conjugate has anti-inflammatory properties by attenuating IL-23-IL-17 signaling in macrophages.
Poland M; Ten Klooster JP; Wang Z; Pieters R; Boekschoten M; Witkamp R; Meijerink J
Biochim Biophys Acta; 2016 Dec; 1861(12 Pt A):2020-2028. PubMed ID: 27663185
[TBL] [Abstract][Full Text] [Related]
14. BATF2 prevents T-cell-mediated intestinal inflammation through regulation of the IL-23/IL-17 pathway.
Kayama H; Tani H; Kitada S; Opasawatchai A; Okumura R; Motooka D; Nakamura S; Takeda K
Int Immunol; 2019 May; 31(6):371-383. PubMed ID: 30753547
[TBL] [Abstract][Full Text] [Related]
15. Targeting the development and effector functions of TH17 cells.
Ghilardi N; Ouyang W
Semin Immunol; 2007 Dec; 19(6):383-93. PubMed ID: 18083530
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses.
Sarin R; Wu X; Abraham C
Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9560-5. PubMed ID: 21606346
[TBL] [Abstract][Full Text] [Related]
17. IL-7/IL-7 Receptor Signaling Differentially Affects Effector CD4+ T Cell Subsets Involved in Experimental Autoimmune Encephalomyelitis.
Arbelaez CA; Glatigny S; Duhen R; Eberl G; Oukka M; Bettelli E
J Immunol; 2015 Sep; 195(5):1974-83. PubMed ID: 26223651
[TBL] [Abstract][Full Text] [Related]
18. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
19. Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad.
Troncone E; Marafini I; Pallone F; Monteleone G
Int Rev Immunol; 2013; 32(5-6):526-33. PubMed ID: 24041379
[TBL] [Abstract][Full Text] [Related]
20. IL-23 and Th17 cytokines in intestinal homeostasis.
Maloy KJ; Kullberg MC
Mucosal Immunol; 2008 Sep; 1(5):339-49. PubMed ID: 19079198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
